Skip To Main Content
Fu-Quan Yang on Muck Rack

Fu-Quan Yang

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Fu-Quan

Contact Fu-Quan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)

|
By Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, Mian-Jing Li, Yong-Rong Liang, Xue-Yao Wang, Hong-Bing Yao, Jie Liu, Pei-Sheng Wu, Ning Peng, Jun-Liang Nong, Ya-Qun Yu, Lin Ye, Ze Su, Chuang Qin, Kang Chen, Yi-He Yan, Fan-Jian Zeng, Shao-Ping Liu, Ming-Song Wu, Fu-Quan Yang, Yong-Cheng Lai, Xiao-Feng Dong, Teng-Meng Zhong, Qing-Qing Pang, Fu-Xin Li, Ai-Qun Liu, Liang Ma, Jian-Hong Zhong, Ping Cen
| Nature Verified
Abstract Whether progression-free survival (PFS) is a valid surrogate endpoint for overall survival (OS) in patients who underwent conversion therapy for hepatocellular carcinoma (HCC) remains uncertain. The present study compares the two survival measures in this patient cohort. Data on unresectable HCC patients undergoing conversion therapy from 20 Chinese medical centers (2019–2023) were retrieved.
Open in Who Shared Issue with article?

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)

|
By Chuang Qin, Ning Peng, Ze Su, Yong-Yu Yang, Qing-Qing Pang, Ying-Yu Zhang, Lin Ye, Xiao-Feng Dong, Wen-Feng Li, Jie Liu, Pei-Sheng Wu, Guo-Dong Wang, Kang Chen, Zhu-Jian Deng, Jia-Yong Su, Zhi-Dong Liu, Jin-Min Wang, Yi Zhang, Bang-De Xiang, Liang Ma, Jian-Hong Zhong, Da-Long Yang, Shao-Ping Liu, Ya-Qun Yu, Jun-Liang Nong, Fan-Jian Zeng, Fu-Quan Yang, Mian-Jing Li, Ming-Song Wu, Xue-Yao Wang, Yong-Rong Liang, Fu-Xin Li, Shu-Chang Chen, Yong-Cheng Lai, Teng-Meng Zhong, Yi-He Yan, Hong-Bing Yao, Xian-Shuang Mao, Jun-Jie Ou, Yao-Zhi Chen, Guo-Gao Qiu, Xiu-Mei Liang
| Nature Verified
Abstract Hepatectomy is considered advisable for some patients with intermediate or advanced hepatocellular carcinoma (HCC). The efficacy and safety of neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors (neoadjuvant triple therapy) for these patients remain unclear.
Open in Who Shared Issue with article?
See all 2 articles